BMI Research: Malaysia in World’s Top Three for Renewable Energy Investment, especially wind and solar power.

https://www.malaymail.com/news/money/2017/02/24/bmi-research-malaysia-in-worlds-top-three-for-renewable-energy-investment/1322413

https://www.malaymail.com/news/money/2017/02/24/bmi-research-malaysia-in-worlds-top-three-for-renewable-energy-investment/1322413

Outlook
As of 31 August 2019, the group has an unbilled order book of RM200.1mn,
(RM100.8mn for residential, commercial and industrial projects, RM83.1mn for
LSSPV projects and the remaining RM16.2mn for others). We estimate this
unbilled order book could provide earnings visibility to the group for the next
12 months.
Protégé Associates, the independent market researcher, expects the outlook
for the solar PV industry in Malaysia to be positive moving forward. The total
solar PV installed capacity in Malaysia stood at 438MWp in 2018, and is
projected to grow to 3,322MW by 2023, representing a CAGR of 50.0%
throughout the period. Factors driving the rapid growth in the solar PV
industry is set to come from the government-led tariff selling programmes.
These include net energy metering programme, the LSSPV programme,
alongside a supply agreement for renewable energy.
Additionally, the Malaysian government is committed towards driving the solar
PV industry in the long term, with its inclusion in the ASEAN Remap, where it
is targeting to achieve a total solar PV installed capacity of 5,800MW by 2025.


High growth industry with 50% growth!!

TA securities TP at 50.5 cents with 44% upside!

Time to fly

Still undervalued according to CIMB

Good morning. Today, we feature a note on CCM Duopharma Biotech Berhad in our FundTech Radar– 23rd Jan 2018. The company is Malaysia’s largest generic pharmaceutical manufacturer by volume and the first pharmaceutical company awarded the Halal Pharmaceuticals certification.

Fundamental Stance
• sales and PAT improved in 9MFY17 by 48.9% and 68.6% respectively, thanks to the increased demand from the public health sector via tenders and supply of traded specialty products
• expects a capex of RM306m for the manufacturing strategy
• net gearing is a comfortable 0.06x.
• paid dividend consistently since FY02 but both div. yield and payout have declined
• The completion of the state-of-the-art plant under its Manufacturing Optimisation Strategy will enable it to increase its production capacity by 50%
• expansion in high value niche therapeutic products
• Permodalan Nasional Bhd (PNB) has recently turned into the largest shareholder
• Other institutional shareholders (EPF, Pacific Mutual Fund & KAF Investment Funds) recently increased their stakes
• currently trading at 19.4x 12-month trailing P/E (7.8% discount to its domestic peers P/E of 21.1x)

Technical Front
Uptrend with rising trading volume.
Resistances: 3.03/3.25/3.35
Supports: 2.62/2.36/2.18

The above information is extracted from CIMB Research Report. For the full research reports, outlook and disclaimers, please logon to your account on www.itradecimb.com.my and click on <Research> Tab under Malaysia.

This FundTech Radar report is intended for educational purposes only. It represents a preliminary assessment of the subject company, and does not represent initiation into CIMB's coverage universe. It does not carry investment ratings and CIMB does not commit to regular updates on an ongoing basis.


23rd Jan 2018
Disclaimers: This distribution is by CIMB Investment Bank Berhad (“CIMB”) in Malaysia only. The views are our own as of this date and subject to change. No further distribution is allowed without our prior written consent. CIMB, its related corporations, affiliates and business partners make no recommendation, offer or invitation to transact in any securities, futures contracts or other instruments. Please make your independent evaluation, consider your own investment objectives and financial situation and consult your own professional advisers before participating in any transaction.

TP for me is 5

Opportunity to buy more hehehe

Definitely oversold! Buy more hehe

KUALA LUMPUR: AmInvestment Research is maintaining its Buy call on Ann Joo
image: https://cdn.thestar.com.my/Themes/img/chart.png

Resources (AJR) with unchanged forecasts and fair value of RM4.34 per share.

It said on Thursday its FV is based on 10 times FY18F fully diluted earnings per share (EPS), in line with the average of its three midcycles’ price-to-earnings (PE) multiples.

“The recent slide in AJR share price was largely triggered by the decline in Chinese steel prices. Steel prices in China have dropped 20% on-month in January 2018 due to price correction from a high base in December 2017 (RMB4,900/tonne equivalent to RM3,000/tonne),” it said.

Recall, steel prices shot up in December 2017 due to the Chinese government's Winter Policy (production curbs between December and March to reduce pollution during the winter season).

Currently, steel prices in China are hovering around RMB4,000/tonne (RM2,500/tonne).

“We make no changes to our forecasts as we do not expect steel prices in China to fall further from the current levels as demand is still strong locally in China coupled with further steel sector reforms that will reduce steel production.

“We maintain our assumptions for average blended steel average selling price (ASP) per tonne of RM2,000, RM2,140 and RM2,250 in FY17-19F respectively, and volume growth projections of 3%, 5% and 5% FY17-19F respectively on the back of stronger domestic demand for steel, particularly, from major infrastructure projects,” it said.

AmInvest Research continues to like AJR because firstly, its dominant position in the local steel market with an estimated market share of 20%.

Secondly, sustained steel prices in the international market due to the phasing out of obsolete steel production capacity in China, while local steel prices will be further supported by safeguard duties on imported steel till April 2020.

Thirdly, rising local demand backed by the rollout of infrastructure projects; and fourthly cost optimisation in production which enables AJR to realise better margins than its competitors.
Read more at https://www.thestar.com.my/business/business-news/2018/01/18/aminvestment-research-retains-buy-on-ann-joo/#cWxLVsTxr5WJcsi1.99

News coming soon

Next week will break RM2

MSS will have favourable impact on future earnings

why sell?

Thanks for the insightful analysis necro, just bought more CCMDBIO shares!

Slow and steady

Buy buy buy good news coming hehehe

Growth stock riding on AirAsia passenger growth, with dividend yield of almost 5%, what are you waiting for?

Buy buy buy

Good year ahead for CCMDBIO

Happy new year to fellow shareholders! This is my top pick for 2018!

https://asia.nikkei.com/Markets/Nikkei-Markets/INTERVIEW-Ann-Joo-To-Raise-Steel-Output-21-In-2018-On-Higher-Orders-Managing-Director